Equity Profile

EXEL

Exelixis, Inc.

Health CareBiotechnology$13.2B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Exelixis is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market performance and acceptance of its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

EXEL Q2-2026 Earnings Preview

Context

Company Snapshot

Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment. With a market cap of $13 billion, it plays a significant role in the health care sector, particularly in oncology, where advancements can lead to improved patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+57.79%

Avg Stock Reaction

-0.79%

Last Quarter Recap

In Q1 2026, Exelixis reported an EPS of $0.87, surpassing estimates by 29.27%. The stock reacted positively, gaining 0.57% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are keen to see if Exelixis can continue its streak of positive earnings surprises. The focus will be on whether the company can maintain its growth trajectory amidst competitive pressures.

Bull Case

If Exelixis delivers strong EPS and revenue growth, it could reinforce investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a decline in stock price, especially given the historical trend of negative reactions post-earnings.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2 2026?

Given Exelixis' strong history of EPS surprises, this number will be critical for investor sentiment.

How is revenue growth trending for the current quarter?

Revenue growth will indicate the company's ability to capture market share and sustain its business model.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Exelixis' ability to leverage its recent product developments, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

Exelixis has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing in a relatively low move, suggesting that expectations may be muted.

Key Risk

If revenue growth exceeds expectations significantly, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Exelixis' ability to maintain its earnings momentum while navigating competitive pressures.

Bull Confirmed If

An EPS of $0.90 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $0.70 would raise concerns about the company's profitability and growth potential.

Pre-Earnings Positioning

Options Market

Implied Move

±1.04%

Historical Avg

±1.1%

In line with history

The options market is pricing in a modest move, suggesting that investors expect relatively stable performance around the earnings report.

Options are pricing ±1.0% while EXEL has averaged ±1.1% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

44.8%

Calls (200K)P/C Ratio: 3.58Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Exelixis beats expectations, history suggests the stock could rise by around 1.14% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors reassess future growth prospects.

Miss

A miss could lead to a decline in stock price, with historical patterns suggesting an average drop of around 0.79%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on competitive landscape and market share.
3Insights into cost management and operational efficiency.
4Guidance on future revenue expectations and market conditions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Exelixis is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market performance and acceptance of its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

EXEL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+57.79%

Avg Stock Reaction

-0.79%

Last Quarter Recap

In Q1 2026, Exelixis reported an EPS of $0.87, surpassing estimates by 29.27%. The stock reacted positively, gaining 0.57% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are keen to see if Exelixis can continue its streak of positive earnings surprises. The focus will be on whether the company can maintain its growth trajectory amidst competitive pressures.

Bull Case

If Exelixis delivers strong EPS and revenue growth, it could reinforce investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a decline in stock price, especially given the historical trend of negative reactions post-earnings.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2 2026?

Given Exelixis' strong history of EPS surprises, this number will be critical for investor sentiment.

How is revenue growth trending for the current quarter?

Revenue growth will indicate the company's ability to capture market share and sustain its business model.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Exelixis' ability to leverage its recent product developments, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

Exelixis has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing in a relatively low move, suggesting that expectations may be muted.

Key Risk

If revenue growth exceeds expectations significantly, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Exelixis' ability to maintain its earnings momentum while navigating competitive pressures.

Bull Confirmed If

An EPS of $0.90 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $0.70 would raise concerns about the company's profitability and growth potential.

Pre-Earnings Positioning

Options Market

Implied Move

±1.04%

Historical Avg

±1.1%

In line with history

The options market is pricing in a modest move, suggesting that investors expect relatively stable performance around the earnings report.

Options are pricing ±1.0% while EXEL has averaged ±1.1% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

44.8%

Calls (200K)P/C Ratio: 3.58Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Exelixis beats expectations, history suggests the stock could rise by around 1.14% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors reassess future growth prospects.

Miss

A miss could lead to a decline in stock price, with historical patterns suggesting an average drop of around 0.79%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on competitive landscape and market share.
3Insights into cost management and operational efficiency.
4Guidance on future revenue expectations and market conditions.